Dr. Cherkasov awarded Tier 1 Canada Research Chair in Precision Cancer Drug Design

Congratulations to Dr. Artem Cherkasov on being awarded the Tier 1 CRC in Precision Cancer Drug Design.

Dr. Artem Cherkasov is a Professor of Medicine at the University of British Columbia (Vancouver, Canada) and Head of the Therapeutics Development Core at Vancouver Prostate Centre. Dr. Cherkasov’s research involves computer-aided drug discovery (CADD), A.I.-guided drug design, cheminformatics, and development of novel, precision cancer therapies. To date, Dr. Cherkasov has co-authored more than 200 research papers, 80 patent filings and several book chapters.

During his tenure at UBC, Dr. Cherkasov has been a principal applicant or co-applicant on a number of successful grants totaling over $80M, and licenced 8 drug candidates to big pharma companies, major international venture funds and spin off companies.

In response to the global COVID-19 pandemic, Dr. Cherkasov's team utilized their novel AI-based platform, Deep Docking (DD), with the structure of the COVID-19 Mpro target, applying DD to process 1.3 billion compounds; within a week, they had identified the top potential drug candidates which they shared with the scientific community.

In 2021 Dr. Cherkasov received UBC Faculty of Medicine Distinguished Achievement Award for Excellence in Fundamental Science.

Click here to read the UBC Faculty of Medicine announcement.